{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:05:50Z","timestamp":1767773150294,"version":"3.40.5"},"reference-count":99,"publisher":"Akademiai Kiado Zrt.","issue":"3","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["PhysInt"],"published-print":{"date-parts":[[2023,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The classical myeloproliferative neoplasms are divided into chronic myeloid leukemia, and the Philadelphia negative polycythemia vera, essential thrombocythemia and primary myelofibrosis. These are heterogenous diseases, originating from the clonal proliferation of myeloid stem cells, resulting in increased mature cell numbers in one or more myeloid lineages. The most commonly seen mutations in the Philadelphia negative myeloproliferative neoplasms include those in Janus kinase, myeloproliferative leukemia protein and the calreticulin genes. Philadelphia negative myeloproliferative neoplasms occur infrequently, with a combined annual incidence of 2.58 per 100,000. There are many overlapping symptoms of Philadelphia negative MPNs, such as fatigue, night sweats, hepatosplenomegaly and circulatory symptoms due to increased cell numbers. Total Symptom Score of the MPN Symptom Assessment Form is used to assess symptom burden on patients. The most worrisome complications are thrombo-hemorrhagic events, and risk stratification is especially important as treatment of disease is based on their category. Phlebotomy and aspirin are the mainstay of treatment in low-risk polycythemia vera and essential thrombocythemia patients, whereas high-risk disease calls for additional cytoreduction, usually with hydroxyurea.<\/jats:p>","DOI":"10.1556\/2060.2023.00261","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T11:54:17Z","timestamp":1693482857000},"page":"227-250","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":2,"title":["BCR::ABL1 negative myeloproliferative neoplasms: A review focused on essential thrombocythemia and polycythemia vera"],"prefix":"10.1556","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5311-4479","authenticated-orcid":true,"given":"Malaz","family":"Khodier","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Semmelweis University, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kl\u00e1ra","family":"Gad\u00f3","sequence":"additional","affiliation":[{"name":"Geriatric Clinic and Center of Nursing Sciences, Faculty of Health Sciences, Semmelweis University, Budapest, Hungary"},{"name":"Department of Clinical Studies, Faculty of Health Sciences, Semmelweis University, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"issue":"7","key":"B1","series-title":"Cancers (Basel)","first-page":"1810","article-title":"Aetiology of myeloproliferative neoplasms","volume":"12","author":"McMullin MF","year":"2020","unstructured":"McMullin MF, Anderson LA. Aetiology of myeloproliferative neoplasms. Cancers (Basel) 2020; 12(7): 1810. https:\/\/doi.org\/10.3390\/cancers12071810."},{"issue":"3","key":"B2","series-title":"N Engl J Med","first-page":"164","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl S","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341(3): 164\u2013172. https:\/\/doi.org\/10.1056\/nejm199907153410306."},{"issue":"11","key":"B3","series-title":"Mol Cell Biol","first-page":"3116","article-title":"Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products","volume":"5","author":"Konopka JB","year":"1985","unstructured":"Konopka JB, Witte ON. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol 1985; 5(11): 3116\u20133123. https:\/\/doi.org\/10.1128\/mcb.5.11.3116-3123.1985."},{"issue":"20","key":"B4","series-title":"Blood","first-page":"2391","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber DA","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et\u00a0al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127(20): 2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544."},{"issue":"1","key":"B5","series-title":"Blood","first-page":"9","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma DP","year":"2015","unstructured":"Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et\u00a0al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015; 126(1): 9\u201316. https:\/\/doi.org\/10.1182\/blood-2015-03-631747."},{"issue":"5129","key":"B6","series-title":"Science","first-page":"1730","article-title":"Tyrosine phosphorylation of DNA binding proteins by multiple cytokines","volume":"261","author":"Larner AC","year":"1993","unstructured":"Larner AC, David M, Feldman GM, Igarashi K, Hackett RH, Webb DS, et\u00a0al. Tyrosine phosphorylation of DNA binding proteins by multiple cytokines. Science 1993; 261(5129): 1730\u20131733. https:\/\/doi.org\/10.1126\/science.8378773."},{"issue":"8","key":"B7","series-title":"Cells","first-page":"854","article-title":"Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation","volume":"8","author":"Perner F","year":"2019","unstructured":"Perner F, Perner C, Ernst T, Heidel FH. Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. Cells 2019; 8(8): 854. https:\/\/doi.org\/10.3390\/cells8080854."},{"issue":"3","key":"B8","series-title":"Cell","first-page":"397","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis","volume":"93","author":"Neubauer H","year":"1998","unstructured":"Neubauer H, Cumano A, M\u00fcller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998; 93(3): 397\u2013409. https:\/\/doi.org\/10.1016\/s0092-8674(00)81168-x."},{"issue":"4","key":"B9","series-title":"Immunity","first-page":"515","article-title":"Inborn errors of human JAKs and STATs","volume":"36","author":"Casanova JL","year":"2012","unstructured":"Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity 2012; 36(4): 515\u2013528. https:\/\/doi.org\/10.1016\/j.immuni.2012.03.016."},{"issue":"12","key":"B10","series-title":"Cells","first-page":"3551","article-title":"Progression of myeloproliferative neoplasms (MPN): diagnostic and therapeutic perspectives","volume":"10","author":"Baumeister J","year":"2021","unstructured":"Baumeister J, Chatain N, Sofias AM, Lammers T, Koschmieder S. Progression of myeloproliferative neoplasms (MPN): diagnostic and therapeutic perspectives. Cells 2021; 10(12): 3551. https:\/\/doi.org\/10.3390\/cells10123551."},{"issue":"5","key":"B11","series-title":"N Engl J Med","first-page":"459","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott LM","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et\u00a0al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356(5): 459\u2013468. https:\/\/doi.org\/10.1056\/NEJMoa065202."},{"key":"B12","series-title":"Ther Clin Risk Manag","first-page":"209","article-title":"Polycythemia vera (PV): update on emerging treatment options","volume":"17","author":"Benevolo G","year":"2021","unstructured":"Benevolo G, Vassallo F, Urbino I, Giai V. Polycythemia vera (PV): update on emerging treatment options. Ther Clin Risk Manag 2021; 17: 209\u2013221. https:\/\/doi.org\/10.2147\/tcrm.S213020."},{"issue":"5","key":"B13","series-title":"J Clin Oncol","first-page":"573","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi A","year":"2011","unstructured":"Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011; 29(5): 573\u2013582. https:\/\/doi.org\/10.1200\/jco.2010.29.8711."},{"issue":"2","key":"B14","series-title":"Br J Haematol","first-page":"268","article-title":"Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient","volume":"156","author":"Rao N","year":"2012","unstructured":"Rao N, Butcher CM, Lewis ID, Ross DM, Melo JV, Scott HS, et\u00a0al. Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient. Br J Haematol 2012; 156(2): 268\u2013270. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08837.x."},{"key":"B15","series-title":"Clin Med Insights Blood Disord","article-title":"The essential thrombocythemia in 2020: what we know and where we still have to dig deep","volume":"13","author":"Accurso V","year":"2020","unstructured":"Accurso V, Santoro M, Mancuso S, Napolitano M, Carlisi M, Mattana M, et\u00a0al. The essential thrombocythemia in 2020: what we know and where we still have to dig deep. Clin Med Insights Blood Disord 2020; 13: 2634853520978210. https:\/\/doi.org\/10.1177\/2634853520978210."},{"issue":"2","key":"B16","series-title":"Curr Opin Hematol","first-page":"117","article-title":"Genetics of the myeloproliferative neoplasms","volume":"18","author":"Abdel-Wahab O.","year":"2011","unstructured":"Abdel-Wahab O. Genetics of the myeloproliferative neoplasms. Curr Opin Hematol 2011; 18(2): 117\u2013123. https:\/\/doi.org\/10.1097\/MOH.0b013e328343998e."},{"issue":"25","key":"B17","series-title":"N Engl J Med","first-page":"2379","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl T","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et\u00a0al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369(25): 2379\u20132390. https:\/\/doi.org\/10.1056\/NEJMoa1311347."},{"issue":"4","key":"B18","series-title":"Curr Hematol Malig Rep","first-page":"261","article-title":"Thrombocytosis and thrombosis: is there really a correlation?","volume":"15","author":"Galvez C","year":"2020","unstructured":"Galvez C, Stein BL. Thrombocytosis and thrombosis: is there really a correlation? Curr Hematol Malig Rep 2020; 15(4): 261\u2013267. https:\/\/doi.org\/10.1007\/s11899-020-00588-z."},{"issue":"23","key":"B19","series-title":"Blood","first-page":"3787","article-title":"JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia","volume":"122","author":"Hobbs CM","year":"2013","unstructured":"Hobbs CM, Manning H, Bennett C, Vasquez L, Severin S, Brain L, et\u00a0al. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood 2013; 122(23): 3787\u20133797. https:\/\/doi.org\/10.1182\/blood-2013-06-501452."},{"issue":"7","key":"B20","series-title":"Blood","first-page":"1136","article-title":"Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm","volume":"124","author":"Lamrani L","year":"2014","unstructured":"Lamrani L, Lacout C, Ollivier V, Denis CV, Gardiner E, Ho Tin Noe B, et\u00a0al. Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. Blood 2014; 124(7): 1136\u20131145. https:\/\/doi.org\/10.1182\/blood-2013-10-530832."},{"issue":"10","key":"B21","series-title":"Blood","first-page":"3472","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani AD","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et\u00a0al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108(10): 3472\u20133476. https:\/\/doi.org\/10.1182\/blood-2006-04-018879."},{"issue":"12","key":"B22","series-title":"Blood Cancer J","first-page":"121","article-title":"MPL-mutated essential thrombocythemia: a morphologic reappraisal","volume":"8","author":"Szuber N","year":"2018","unstructured":"Szuber N, Hanson CA, Lasho TL, Finke C, Ketterling RP, Pardanani A, et\u00a0al. MPL-mutated essential thrombocythemia: a morphologic reappraisal. Blood Cancer J 2018; 8(12): 121. https:\/\/doi.org\/10.1038\/s41408-018-0159-3."},{"issue":"16","key":"B23","series-title":"Blood","first-page":"2507","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi A","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et\u00a0al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014; 124(16): 2507\u20132513; quiz 615. https:\/\/doi.org\/10.1182\/blood-2014-05-579136."},{"issue":"1","key":"B24","series-title":"Hemasphere","first-page":"e333","article-title":"Mutant calreticulin in the myeloproliferative neoplasms","volume":"4","author":"Prins D","year":"2020","unstructured":"Prins D, Gonz\u00e1lez Arias C, Klampfl T, Grinfeld J, Green AR. Mutant calreticulin in the myeloproliferative neoplasms. Hemasphere 2020; 4(1): e333. https:\/\/doi.org\/10.1097\/hs9.0000000000000333."},{"key":"B25","series-title":"F1000Res","first-page":"700","article-title":"Recent advances in understanding myelofibrosis and essential thrombocythemia","volume":"5","author":"Vainchenker W","year":"2016","unstructured":"Vainchenker W, Constantinescu SN, Plo I. Recent advances in understanding myelofibrosis and essential thrombocythemia. F1000Res 2016; 5: 700. https:\/\/doi.org\/10.12688\/f1000research.8081.1."},{"issue":"4","key":"B26","series-title":"Am J Hematol","first-page":"450","article-title":"CALR mutation studies in chronic neutrophilic leukemia","volume":"89","author":"Lasho TL","year":"2014","unstructured":"Lasho TL, Elliott MA, Pardanani A, Tefferi A. CALR mutation studies in chronic neutrophilic leukemia. Am J Hematol 2014; 89(4): 450. https:\/\/doi.org\/10.1002\/ajh.23665."},{"key":"B27","series-title":"Blood Rev","article-title":"Current management strategies for polycythemia vera and essential thrombocythemia","volume":"42","author":"Guglielmelli P","year":"2020","unstructured":"Guglielmelli P, Vannucchi AM. Current management strategies for polycythemia vera and essential thrombocythemia. Blood Rev 2020; 42: 100714. https:\/\/doi.org\/10.1016\/j.blre.2020.100714."},{"issue":"6","key":"B28","series-title":"Am J Hematol","first-page":"581","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh GJ","year":"2014","unstructured":"Titmarsh GJ, Duncombe AS, McMullin MF, O'Rorke M, Mesa R, De Vocht F, et\u00a0al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol 2014; 89(6): 581\u2013587. https:\/\/doi.org\/10.1002\/ajh.23690."},{"issue":"2","key":"B29","series-title":"Am J Hematol","first-page":"175","article-title":"Environmental, lifestyle, and familial\/ethnic factors associated with myeloproliferative neoplasms","volume":"87","author":"Anderson LA","year":"2012","unstructured":"Anderson LA, Duncombe AS, Hughes M, Mills ME, Wilson JC, McMullin MF. Environmental, lifestyle, and familial\/ethnic factors associated with myeloproliferative neoplasms. Am J Hematol 2012; 87(2): 175\u2013182. https:\/\/doi.org\/10.1002\/ajh.22212."},{"key":"B30","series-title":"J Hematol Oncol","first-page":"18","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"Kaifie A","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D, Maintz C, H\u00e4nel M, Gattermann N, et\u00a0al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 2016; 9: 18. https:\/\/doi.org\/10.1186\/s13045-016-0242-9."},{"issue":"6","key":"B31","series-title":"Br J Cancer","first-page":"853","article-title":"The Northern region Children's malignant disease registry 1968\u201382: incidence and survival","volume":"56","author":"Craft AW","year":"1987","unstructured":"Craft AW, Amineddine HA, Scott JE, Wagget J. The Northern region Children's malignant disease registry 1968\u201382: incidence and survival. Br J Cancer 1987; 56(6): 853\u2013858. https:\/\/doi.org\/10.1038\/bjc.1987.305."},{"issue":"4","key":"B32","series-title":"Nat Genet","first-page":"446","article-title":"JAK2 haplotype is a major risk factor for the\u00a0development of myeloproliferative neoplasms","volume":"41","author":"Jones AV","year":"2009","unstructured":"Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et\u00a0al. JAK2 haplotype is a major risk factor for the\u00a0development of myeloproliferative neoplasms. Nat Genet 2009; 41(4): 446\u2013449. https:\/\/doi.org\/10.1038\/ng.334."},{"issue":"6","key":"B33","series-title":"Leukemia","first-page":"1371","article-title":"The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms","volume":"28","author":"Oddsson A","year":"2014","unstructured":"Oddsson A, Kristinsson SY, Helgason H, Gudbjartsson DF, Masson G, Sigurdsson A, et\u00a0al. The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia 2014; 28(6): 1371\u20131374. https:\/\/doi.org\/10.1038\/leu.2014.48."},{"issue":"3","key":"B34","series-title":"Leuk Lymphoma","first-page":"251","article-title":"High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel","volume":"7","author":"Chaiter Y","year":"1992","unstructured":"Chaiter Y, Brenner B, Aghai E, Tatarsky I. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma 1992; 7(3): 251\u2013255. https:\/\/doi.org\/10.3109\/10428199209053630."},{"issue":"4","key":"B35","series-title":"Hematol Cell Ther","first-page":"159","article-title":"Epidemiological data in polycythaemia vera: a study of 842 cases","volume":"40","author":"Najean Y","year":"1998","unstructured":"Najean Y, Rain JD, Billotey C. Epidemiological data in polycythaemia vera: a study of 842 cases. Hematol Cell Ther 1998; 40(4): 159\u2013165."},{"issue":"10","key":"B36","series-title":"Nat Genet","first-page":"1131","article-title":"Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies","volume":"47","author":"Saliba J","year":"2015","unstructured":"Saliba J, Saint-Martin C, Di Stefano A, Lenglet G, Marty C, Keren B, et\u00a0al. Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nat Genet 2015; 47(10): 1131\u20131140. https:\/\/doi.org\/10.1038\/ng.3380."},{"issue":"3","key":"B37","series-title":"Blood","first-page":"362","article-title":"Germline RBBP6 mutations in familial myeloproliferative neoplasms","volume":"127","author":"Harutyunyan AS","year":"2016","unstructured":"Harutyunyan AS, Giambruno R, Krendl C, Stukalov A, Klampfl T, Berg T, et\u00a0al. Germline RBBP6 mutations in familial myeloproliferative neoplasms. Blood 2016; 127(3): 362\u2013365. https:\/\/doi.org\/10.1182\/blood-2015-09-668673."},{"issue":"7","key":"B38","series-title":"Obesity (Silver Spring)","first-page":"1187","article-title":"Obesity and related risk of myeloproliferative neoplasms among israeli adolescents","volume":"25","author":"Leiba A","year":"2017","unstructured":"Leiba A, Duek A, Afek A, Derazne E, Leiba M. Obesity and related risk of myeloproliferative neoplasms among israeli adolescents. Obesity (Silver Spring) 2017; 25(7): 1187\u20131190. https:\/\/doi.org\/10.1002\/oby.21863."},{"issue":"5","key":"B39","series-title":"Br J Cancer","first-page":"879","article-title":"Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study","volume":"107","author":"Kroll ME","year":"2012","unstructured":"Kroll ME, Murphy F, Pirie K, Reeves GK, Green J, Beral V. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study. Br J Cancer 2012; 107(5): 879\u2013887. https:\/\/doi.org\/10.1038\/bjc.2012.333."},{"issue":"4","key":"B40","series-title":"Int J Cancer","first-page":"948","article-title":"Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study","volume":"147","author":"Podoltsev NA","year":"2020","unstructured":"Podoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, et\u00a0al. Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study. Int J Cancer 2020; 147(4): 948\u2013957. https:\/\/doi.org\/10.1002\/ijc.32853."},{"issue":"1","key":"B41","series-title":"Br J Haematol","first-page":"83","article-title":"Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: a retrospective cohort study","volume":"193","author":"S\u00f8rensen AL","year":"2021","unstructured":"S\u00f8rensen AL, Knudsen TA, Skov V, Kj\u00e6r L, Holm N, Ellervik C, et\u00a0al. Smoking impairs molecular response, and reduces overall survival in patients with chronic myeloproliferative neoplasms: a retrospective cohort study. Br J Haematol 2021; 193(1): 83\u201392. https:\/\/doi.org\/10.1111\/bjh.17130."},{"issue":"1","key":"B42","series-title":"Cancer","first-page":"68","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa RA","year":"2007","unstructured":"Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et\u00a0al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007; 109(1): 68\u201376. https:\/\/doi.org\/10.1002\/cncr.22365."},{"issue":"9","key":"B43","series-title":"Leuk Res","first-page":"1199","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa RA","year":"2009","unstructured":"Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, et\u00a0al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009; 33(9): 1199\u20131203. https:\/\/doi.org\/10.1016\/j.leukres.2009.01.035."},{"issue":"21","key":"B44","series-title":"Cancer","first-page":"4869","article-title":"Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial","volume":"117","author":"Mesa RA","year":"2011","unstructured":"Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, et\u00a0al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer 2011; 117(21): 4869\u20134877. https:\/\/doi.org\/10.1002\/cncr.26129."},{"issue":"33","key":"B45","series-title":"J Clin Oncol","first-page":"4098","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel RM","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et\u00a0al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012; 30(33): 4098\u20134103. https:\/\/doi.org\/10.1200\/jco.2012.42.3863."},{"issue":"10","key":"B46","series-title":"Am J Hematol","first-page":"864","article-title":"Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls","volume":"90","author":"Anderson LA","year":"2015","unstructured":"Anderson LA, James G, Duncombe AS, Mesa R, Scherber R, Dueck AC, et\u00a0al. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol 2015; 90(10): 864\u2013870. https:\/\/doi.org\/10.1002\/ajh.24098."},{"issue":"3","key":"B47","series-title":"Hematol Transfus Cell Ther","first-page":"321","article-title":"Myeloproliferative neoplasm symptom assessment form - total symptom score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese","volume":"44","author":"Guaran\u00e1 M","year":"2022","unstructured":"Guaran\u00e1 M, Soares A, Daumas A, Biasoli I, Solza C. Myeloproliferative neoplasm symptom assessment form - total symptom score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese. Hematol Transfus Cell Ther 2022; 44(3): 321\u2013327. https:\/\/doi.org\/10.1016\/j.htct.2020.10.966."},{"issue":"4","key":"B48","series-title":"Mayo Clin Proc","first-page":"599","article-title":"3023 Mayo clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups","volume":"94","author":"Szuber N","year":"2019","unstructured":"Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, et\u00a0al. 3023 Mayo clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc 2019; 94(4): 599\u2013610. https:\/\/doi.org\/10.1016\/j.mayocp.2018.08.022."},{"issue":"12","key":"B49","series-title":"Leukemia","first-page":"3339","article-title":"Polycythemia vera: historical oversights, diagnostic details, and therapeutic views","volume":"35","author":"Tefferi A","year":"2021","unstructured":"Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia 2021; 35(12): 3339\u20133351. https:\/\/doi.org\/10.1038\/s41375-021-01401-3."},{"issue":"2","key":"B50","series-title":"Clin Adv Hematol Oncol","first-page":"76","article-title":"A review of essential thrombocythemia and its complications","volume":"21","author":"Babakhanlou R","year":"2023","unstructured":"Babakhanlou R, Masarova L, Verstovsek S. A review of essential thrombocythemia and its complications. Clin Adv Hematol Oncol 2023; 21(2): 76\u201384."},{"issue":"6","key":"B51","series-title":"J Clin Oncol","first-page":"761","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui T","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et\u00a0al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29(6): 761\u2013770. https:\/\/doi.org\/10.1200\/jco.2010.31.8436."},{"issue":"10","key":"B52","series-title":"J Clin Oncol","first-page":"2224","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli R","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et\u00a0al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23(10): 2224\u20132232. https:\/\/doi.org\/10.1200\/jco.2005.07.062."},{"issue":"11","key":"B53","series-title":"Blood Adv","first-page":"1729","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis","volume":"3","author":"Carobbio A","year":"2019","unstructured":"Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv 2019; 3(11): 1729\u20131737. https:\/\/doi.org\/10.1182\/bloodadvances.2019000211."},{"issue":"1","key":"B54","series-title":"Ther Adv Hematol","first-page":"21","article-title":"JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment","volume":"2","author":"Vannucchi AM","year":"2011","unstructured":"Vannucchi AM, Pieri L, Guglielmelli P. JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Ther Adv Hematol 2011; 2(1): 21\u201332. https:\/\/doi.org\/10.1177\/2040620710394474."},{"issue":"1","key":"B55","series-title":"Hematology","first-page":"157","article-title":"Validation and reliability of current\u00a0guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan","volume":"27","author":"Baba T","year":"2022","unstructured":"Baba T, Hashimoto Y, Yasuda H, Araki M, Edahiro Y, Morishita S, et\u00a0al. Validation and reliability of current\u00a0guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan. Hematology 2022; 27(1): 157\u2013166. https:\/\/doi.org\/10.1080\/16078454.2021.2022848."},{"issue":"11","key":"B56","series-title":"Blood Cancer J","first-page":"e369","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with whom-defined essential thrombocythemia","volume":"5","author":"Barbui T","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, et\u00a0al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with whom-defined essential thrombocythemia. Blood Cancer J 2015; 5(11): e369. https:\/\/doi.org\/10.1038\/bcj.2015.94."},{"issue":"4","key":"B57","series-title":"Hematol Oncol","first-page":"434","article-title":"Comparison between thrombotic risk scores in essential thrombocythemia and survival implications","volume":"37","author":"Santoro M","year":"2019","unstructured":"Santoro M, Accurso V, Mancuso S, Carlisi M, Raso S, Tarantino G, et\u00a0al. Comparison between thrombotic risk scores in essential thrombocythemia and survival implications. Hematol Oncol 2019; 37(4): 434\u2013437. https:\/\/doi.org\/10.1002\/hon.2670."},{"issue":"10","key":"B58","series-title":"Oncol Res Treat","first-page":"526","article-title":"Cardiovascular risk in polycythemia vera: thrombotic risk and survival: can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors?","volume":"43","author":"Mancuso S","year":"2020","unstructured":"Mancuso S, Santoro M, Accurso V, Agliastro G, Raso S, Di Piazza F, et\u00a0al. Cardiovascular risk in polycythemia vera: thrombotic risk and survival: can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors? Oncol Res Treat 2020; 43(10): 526\u2013530. https:\/\/doi.org\/10.1159\/000509376."},{"issue":"4","key":"B59","series-title":"Oncol Res Treat","first-page":"201","article-title":"No impact of the increased number of cardiovascular risk factors on thrombosis and survival in polycythemia vera","volume":"44","author":"Kre\u010dak I","year":"2021","unstructured":"Kre\u010dak I, Mori\u0107 Peri\u0107 M, Zekanovi\u0107 I, Holik H, Coha B, Gveri\u0107-Kre\u010dak V, et\u00a0al. No impact of the increased number of cardiovascular risk factors on thrombosis and survival in polycythemia vera. Oncol Res Treat 2021; 44(4): 201\u2013203. https:\/\/doi.org\/10.1159\/000514347."},{"issue":"5","key":"B60","series-title":"Ann Hematol","first-page":"935","article-title":"Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions","volume":"101","author":"Goulart H","year":"2022","unstructured":"Goulart H, Mascarenhas J, Tremblay D. Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions. Ann Hematol 2022; 101(5): 935\u2013951. https:\/\/doi.org\/10.1007\/s00277-022-04826-7."},{"issue":"4","key":"B61","series-title":"Blood","first-page":"341","article-title":"How I treat polycythemia vera","volume":"134","author":"Spivak JL","year":"2019","unstructured":"Spivak JL. How I treat polycythemia vera. Blood 2019; 134(4): 341\u2013352. https:\/\/doi.org\/10.1182\/blood.2018834044."},{"issue":"1","key":"B62","series-title":"Am J Hematol","first-page":"133","article-title":"Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management","volume":"94","author":"Tefferi A","year":"2019","unstructured":"Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 2019; 94(1): 133\u2013143. https:\/\/doi.org\/10.1002\/ajh.25303."},{"issue":"1","key":"B63","series-title":"Am J Hematol","first-page":"145","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi A","year":"2021","unstructured":"Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 2021; 96(1): 145\u2013162. https:\/\/doi.org\/10.1002\/ajh.26050."},{"key":"B64","series-title":"Leuk Res","article-title":"Patients with post polycythemia vera\u00a0myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential\u00a0thrombocythemia myelofibrosis","volume":"119","author":"Lucijanic M","year":"2022","unstructured":"Lucijanic M, Krecak I, Soric E, Sabljic A, Galusic D, Holik H, et\u00a0al. Patients with post polycythemia vera\u00a0myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential\u00a0thrombocythemia myelofibrosis. Leuk Res 2022; 119: 106905. https:\/\/doi.org\/10.1016\/j.leukres.2022.106905."},{"issue":"12","key":"B65","series-title":"Am J Hematol","first-page":"1599","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi A","year":"2020","unstructured":"Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 2020; 95(12): 1599\u20131613. https:\/\/doi.org\/10.1002\/ajh.26008."},{"issue":"5","key":"B66","series-title":"Leukemia","first-page":"1057","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui T","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et\u00a0al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 2018; 32(5): 1057\u20131069. https:\/\/doi.org\/10.1038\/s41375-018-0077-1."},{"issue":"4","key":"B67","series-title":"Am J Clin Pathol","first-page":"408","article-title":"Laboratory investigation of myeloproliferative neoplasms (MPNs): recommendations of the Canadian Mpn group","volume":"146","author":"Busque L","year":"2016","unstructured":"Busque L, Porwit A, Day R, Olney HJ, Leber B, \u00c9thier V, et\u00a0al. Laboratory investigation of myeloproliferative neoplasms (MPNs): recommendations of the Canadian Mpn group. Am J Clin Pathol 2016; 146(4): 408\u2013422. https:\/\/doi.org\/10.1093\/ajcp\/aqw131."},{"issue":"7","key":"B68","series-title":"Am J Med","first-page":"e150","article-title":"Pseudohyperkalemia: three cases and a review of literature","volume":"135","author":"Saleh-Anaraki K","year":"2022","unstructured":"Saleh-Anaraki K, Jain A, Wilcox CS, Pourafshar N. Pseudohyperkalemia: three cases and a review of literature. Am J Med 2022; 135(7): e150\u2013e154. https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.036."},{"issue":"7","key":"B69","series-title":"Asian Pac J Cancer Prev","first-page":"2079","article-title":"Platelet function tests and inflammatory markers for the differentiation of primary thrombocytosis and secondary thrombocytosis","volume":"20","author":"Kanya P","year":"2019","unstructured":"Kanya P, Rattarittamrong E, Wongtakan O, Rattanathammethee T, Chai-Adisaksopha C, Tantiworawit A, et\u00a0al. Platelet function tests and inflammatory markers for the differentiation of primary thrombocytosis and secondary thrombocytosis. Asian Pac J Cancer Prev 2019; 20(7): 2079\u20132085. https:\/\/doi.org\/10.31557\/apjcp.2019.20.7.2079."},{"issue":"1","key":"B70","series-title":"Eur J Haematol","first-page":"46","article-title":"The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera","volume":"104","author":"Nersesjan V","year":"2020","unstructured":"Nersesjan V, Zervides KA, S\u00f8rensen AL, Kjaer L, Skov V, Hasselbalch HC. The red blood cell count and the erythrocyte sedimentation rate in the diagnosis of polycythaemia vera. Eur J Haematol 2020; 104(1): 46\u201354. https:\/\/doi.org\/10.1111\/ejh.13334."},{"key":"B71","series-title":"Thrombosis","article-title":"The CYTO-PV: a large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera","volume":"2011","author":"Marchioli R","year":"2011","unstructured":"Marchioli R, Finazzi G, Specchia G, Masciulli A, Mennitto MR, Barbui T. The CYTO-PV: a large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis 2011; 2011: 794240. https:\/\/doi.org\/10.1155\/2011\/794240."},{"issue":"5","key":"B72","series-title":"Blood Rev","first-page":"205","article-title":"Front-line therapy in polycythemia vera and essential thrombocythemia","volume":"26","author":"Barbui T","year":"2012","unstructured":"Barbui T, Finazzi MC, Finazzi G. Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev 2012; 26(5): 205\u2013211. https:\/\/doi.org\/10.1016\/j.blre.2012.06.002."},{"issue":"2","key":"B73","series-title":"N Engl J Med","first-page":"114","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi R","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et\u00a0al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350(2): 114\u2013124. https:\/\/doi.org\/10.1056\/NEJMoa035572."},{"issue":"8","key":"B74","series-title":"Platelets","first-page":"528","article-title":"Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in\u00a0patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia","volume":"17","author":"Michiels JJ","year":"2006","unstructured":"Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Neumann HA, et\u00a0al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in\u00a0patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets 2006; 17(8): 528\u2013544. https:\/\/doi.org\/10.1080\/09537100600758677."},{"issue":"1","key":"B75","series-title":"Am J Cardiovasc Drugs","first-page":"63","article-title":"Once- versus twice-daily aspirin in patients at high risk of thrombotic events: systematic review and meta-analysis","volume":"21","author":"Mainoli B","year":"2021","unstructured":"Mainoli B, Duarte GS, Costa J, Ferreira J, Caldeira D. Once- versus twice-daily aspirin in patients at high risk of thrombotic events: systematic review and meta-analysis. Am J Cardiovasc Drugs 2021; 21(1): 63\u201371. https:\/\/doi.org\/10.1007\/s40256-020-00409-x."},{"issue":"3","key":"B76","series-title":"Platelets","first-page":"322","article-title":"Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis","volume":"30","author":"Larsen ML","year":"2019","unstructured":"Larsen ML, Pedersen OH, Hvas AM, Niekerk P, B\u00f8nl\u00f8kke S, Kristensen SD, et\u00a0al. Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. Platelets 2019; 30(3): 322\u2013328. https:\/\/doi.org\/10.1080\/09537104.2018.1430356."},{"issue":"2","key":"B77","series-title":"Blood","first-page":"171","article-title":"A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"Rocca B","year":"2020","unstructured":"Rocca B, Tosetto A, Betti S, Soldati D, Petrucci G, Rossi E, et\u00a0al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood 2020; 136(2): 171\u2013182. https:\/\/doi.org\/10.1182\/blood.2019004596."},{"issue":"6","key":"B78","series-title":"Blood Cancer J","first-page":"49","article-title":"The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting","volume":"8","author":"De Stefano V","year":"2018","unstructured":"De Stefano V, Rocca B, Tosetto A, Soldati D, Petrucci G, Beggiato E, et\u00a0al. The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. Blood Cancer J 2018; 8(6): 49. https:\/\/doi.org\/10.1038\/s41408-018-0078-3."},{"issue":"3","key":"B79","series-title":"Lancet Haematol","first-page":"e175","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial","volume":"8","author":"Barbui T","year":"2021","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, et\u00a0al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol 2021; 8(3): e175\u2013e184. https:\/\/doi.org\/10.1016\/S2352-3026(20)30373-2."},{"issue":"4","key":"B80","series-title":"Lancet Haematol","first-page":"e301","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021\u00a0recommendations","volume":"9","author":"Marchetti M","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, et\u00a0al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021\u00a0recommendations. Lancet Haematol 2022; 9(4): e301\u2013e311. https:\/\/doi.org\/10.1016\/s2352-3026(22)00046-1."},{"issue":"1","key":"B81","series-title":"Br J Haematol","first-page":"81","article-title":"Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia","volume":"152","author":"Hern\u00e1ndez-Boluda JC","year":"2011","unstructured":"Hern\u00e1ndez-Boluda JC, Alvarez-Larr\u00e1n A, G\u00f3mez M, Angona A, Amat P, Bellosillo B, et\u00a0al. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol 2011; 152(1): 81\u201388. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08430.x."},{"issue":"2","key":"B82","series-title":"Leukemia","first-page":"277","article-title":"A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group","volume":"21","author":"Barosi G","year":"2007","unstructured":"Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, et\u00a0al. A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 2007; 21(2): 277\u2013280. https:\/\/doi.org\/10.1038\/sj.leu.2404473."},{"issue":"5","key":"B83","series-title":"Br J Haematol","first-page":"786","article-title":"Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera","volume":"172","author":"Alvarez-Larr\u00e1n A","year":"2016","unstructured":"Alvarez-Larr\u00e1n A, Kerguelen A, Hern\u00e1ndez-Boluda JC, P\u00e9rez-Encinas M, Ferrer-Mar\u00edn F, B\u00e1rez A, et\u00a0al. Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol 2016; 172(5): 786\u2013793. https:\/\/doi.org\/10.1111\/bjh.13886."},{"issue":"4","key":"B84","series-title":"Blood","first-page":"863","article-title":"Long-term use of anagrelide in young patients with essential thrombocythemia","volume":"97","author":"Storen EC","year":"2001","unstructured":"Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001; 97(4): 863\u2013866. https:\/\/doi.org\/10.1182\/blood.v97.4.863."},{"issue":"1","key":"B85","series-title":"N Engl J Med","first-page":"33","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison CN","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et\u00a0al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353(1): 33\u201345. https:\/\/doi.org\/10.1056\/NEJMoa043800."},{"key":"B86","series-title":"Leuk Res","article-title":"Anagrelide in essential thrombocythemia: efficacy and long-term consequences in young patient population","volume":"123","author":"Bieniaszewska M","year":"2022","unstructured":"Bieniaszewska M, Sobieralski P, Leszczy\u0144ska A, Dutka M. Anagrelide in essential thrombocythemia: efficacy and long-term consequences in young patient population. Leuk Res 2022; 123: 106962. https:\/\/doi.org\/10.1016\/j.leukres.2022.106962."},{"issue":"3","key":"B87","series-title":"Eur J Haematol","first-page":"335","article-title":"Anagrelide in essential thrombocythemia (ET): results from 150 patients over 25 years by the \u201cPh1-negative myeloproliferative neoplasms latium group\u201d","volume":"105","author":"Mazzucconi MG","year":"2020","unstructured":"Mazzucconi MG, Baldacci E, Latagliata R, Breccia M, Paoloni F, Di Veroli A, et\u00a0al. Anagrelide in essential thrombocythemia (ET): results from 150 patients over 25 years by the \u201cPh1-negative myeloproliferative neoplasms latium group\u201d. Eur J Haematol 2020; 105(3): 335\u2013343. https:\/\/doi.org\/10.1111\/ejh.13454."},{"issue":"2","key":"B88","series-title":"Eur J Haematol","first-page":"116","article-title":"Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-na\u00efve essential thrombocythemia patients in a real-world setting","volume":"103","author":"Ito T","year":"2019","unstructured":"Ito T, Hashimoto Y, Tanaka Y, Nakaya A, Fujita S, Satake A, et\u00a0al. Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-na\u00efve essential thrombocythemia patients in a real-world setting. Eur J Haematol 2019; 103(2): 116\u2013123. https:\/\/doi.org\/10.1111\/ejh.13265."},{"issue":"18","key":"B89","series-title":"Blood","first-page":"1498","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub A","year":"2019","unstructured":"Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, et\u00a0al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood 2019; 134(18): 1498\u20131509. https:\/\/doi.org\/10.1182\/blood.2019000428."},{"issue":"11","key":"B90","series-title":"Leukemia","first-page":"1990","article-title":"Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms","volume":"22","author":"Kiladjian JJ","year":"2008","unstructured":"Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008; 22(11): 1990\u20131998. https:\/\/doi.org\/10.1038\/leu.2008.280."},{"issue":"4","key":"B91","series-title":"Lancet Haematol","first-page":"e165","article-title":"Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial","volume":"4","author":"Masarova L","year":"2017","unstructured":"Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, et\u00a0al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol 2017; 4(4): e165\u2013e175. https:\/\/doi.org\/10.1016\/s2352-3026(17)30030-3."},{"issue":"7","key":"B92","series-title":"Cancers (Basel)","first-page":"1954","article-title":"Use of interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature","volume":"12","author":"How J","year":"2020","unstructured":"How J, Hobbs G. Use of interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature. Cancers (Basel) 2020; 12(7): 1954. https:\/\/doi.org\/10.3390\/cancers12071954."},{"issue":"8","key":"B93","series-title":"Blood","first-page":"3065","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian JJ","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et\u00a0al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112(8): 3065\u20133072. https:\/\/doi.org\/10.1182\/blood-2008-03-143537."},{"issue":"2","key":"B94","series-title":"Blood Adv","first-page":"380","article-title":"Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis","volume":"4","author":"Masciulli A","year":"2020","unstructured":"Masciulli A, Ferrari A, Carobbio A, Ghirardi A, Barbui T. Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis. Blood Adv 2020; 4(2): 380\u2013386. https:\/\/doi.org\/10.1182\/bloodadvances.2019001158."},{"issue":"7","key":"B95","series-title":"Haematologica","first-page":"821","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek S","year":"2016","unstructured":"Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, et\u00a0al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica 2016; 101(7): 821\u2013829. https:\/\/doi.org\/10.3324\/haematol.2016.143644."},{"issue":"6","key":"B96","series-title":"Expert Opin Investig Drugs","first-page":"525","article-title":"Givinostat: an emerging treatment for polycythemia vera","volume":"29","author":"Chifotides HT","year":"2020","unstructured":"Chifotides HT, Bose P, Verstovsek S. Givinostat: an emerging treatment for polycythemia vera. Expert Opin Investig Drugs 2020; 29(6): 525\u2013536. https:\/\/doi.org\/10.1080\/13543784.2020.1761323."},{"issue":"Supplement 1","key":"B97","series-title":"Blood","first-page":"1784","article-title":"A phase 2 study of the LSD1 inhibitor\u00a0Bomedemstat (IMG-7289) for the treatment of essential thrombocythemia (ET)","volume":"140","author":"Gill H","year":"2022","unstructured":"Gill H, Palandri F, Ross DM, Cochrane T, Tate C, Lane SW, et\u00a0al. A phase 2 study of the LSD1 inhibitor\u00a0Bomedemstat (IMG-7289) for the treatment of essential thrombocythemia (ET). Blood 2022; 140(Supplement 1): 1784\u20131787. https:\/\/doi.org\/10.1182\/blood-2022-159047."},{"issue":"19","key":"B98","series-title":"Blood","first-page":"2871","article-title":"Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth","volume":"139","author":"Gotlib J","year":"2022","unstructured":"Gotlib J. Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth. Blood 2022; 139(19): 2871\u20132881. https:\/\/doi.org\/10.1182\/blood.2022015680."},{"issue":"4","key":"B99","series-title":"Haematologica","first-page":"312","article-title":"Patients with thrombocytosis have normal or slightly elevated thrombopoietin levels","volume":"84","author":"Espa\u00f1ol I","year":"1999","unstructured":"Espa\u00f1ol I, Hern\u00e1ndez A, Cort\u00e9s M, Mateo J, Pujol-Moix N. Patients with thrombocytosis have normal or slightly elevated thrombopoietin levels. Haematologica 1999; 84(4): 312\u2013316."}],"container-title":["Physiology International"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/2060\/110\/3\/article-p227.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/view\/journals\/2060\/110\/3\/article-p227.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/view\/journals\/2060\/110\/3\/article-p227.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T13:15:02Z","timestamp":1693919702000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/2060\/110\/3\/article-p227.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":99,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1556\/2060.2023.00261","relation":{},"ISSN":["2498-602X","2677-0164"],"issn-type":[{"type":"print","value":"2498-602X"},{"type":"electronic","value":"2677-0164"}],"subject":[],"published":{"date-parts":[[2023,9,5]]}}}